🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
1023 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
2025-523500-72-00Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase I
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
2025-524080-20-00Metastatic castration resistant prostate cancer
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Germany
17/08/2026
Phase II
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke
2025-521693-33-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
17/08/2026
Phase III
C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
2025-523447-35-02Pneumoccoccal Immunisation
Pfizer Inc.
Bacterial Infections and Mycoses
Spain, Finland, Poland, Germany, Greece, Hungary, Italy
17/08/2026
Phase I/II
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
2025-524915-36-00Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Germany, Spain, Finland, France
17/08/2026
Phase III
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00heart failure
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)
2026-525454-11-00Diagnosis of primary ITP according to the 2019 Internationa…
Amgen Inc.
Hemic and Lymphatic Diseases
Spain, Hungary, Germany
14/08/2026
Phase II
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
2026-525550-11-00Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
Male Urogenital Diseases
Spain
14/08/2026
Phase IV
Phase IV Low Intervention Clinical Trial to Study Biomarkers of "inflammageing" and Senescence in Pre-diabetic Patients Treated with Metformin: A Study nested within the project “NLRP3 Inflammasome at the Crossroad of Vascular Inflammageing: A Novel Target for Senomorphic Drugs”.
2026-527080-15-00Pre-diabetic Patients
Universidad Autonoma De Madrid
Metabolism
Spain
14/08/2026
Phase II
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00HR-positive/HER2-negative advanced breast cancer
Medica Scientia Innovation Research S.L.
Neoplasms
Spain, Italy, Germany
13/08/2026
Phase III
SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients
2025-523444-12-00Breast Cancer
AstraZeneca AB
Neoplasms
Poland, Spain, France, Germany, Italy
13/08/2026
Phase IV
A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation
2025-524392-23-00Chronic obstructive pulmonary disease (COPD)
Regeneron Pharmaceuticals Inc.
Respiratory Tract Diseases
Belgium, Italy, Spain
13/08/2026
Phase III
International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies
2025-524676-32-00Patients suffering from rhinitis / rhinoconjunctivitis, wit…
ROXALL Medizin GmbH
Diagnosis
Germany, Spain
12/08/2026
Phase I
A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors
2025-524805-34-00Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
Neoplasms
Italy, Netherlands, France, Spain
11/08/2026
Phase I
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
2025-522532-14-00Advanced solid tumors
Pfizer Inc.
Neoplasms
Netherlands, France, Spain
11/08/2026
Phase I/II
Bioequivalence clinical trial of two formulations of quetiapine.
2026-527162-72-00Healthy participants
Laboratorios Alter S.A.
Mental Disorders
Spain
11/08/2026
Phase II
J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C
2025-524974-41-00Irritable Bowel Syndrome - Constipation
Eli Lilly & Co.
Digestive System Diseases
Belgium, Spain
11/08/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
2026-525217-31-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Italy, Belgium, Germany, France, Spain
10/08/2026
Phase II
Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.
2025-521689-86-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
10/08/2026
Phase I
A Phase 1 Trial of GEN1119 in Participants with Solid Tumors
2026-525610-62-00Solid Tumors
Genmab A/S
Neoplasms
Spain, France
10/08/2026
Phase III
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)
2025-522824-29-00Primary IgAN
Novartis Pharma AG
Immune system processes
France, Spain
10/08/2026
Phase III
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase III
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
2025-523333-26-00Graves' Disease (GD)
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase IV
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…
Centre Hospitalier Universitaire Vaudois
Virus Diseases
France, Spain
07/08/2026
Rows per page Showing 76–100 of 1023
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.